-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LgvG1/erye/A1z9yPnsTMm4Ko7BpQGL465phhPEzOrFVxaKUAou9N2MBW5B8uBpF 4qdxI2UOdyJWq4CifdGvVg== 0000000000-06-016697.txt : 20070112 0000000000-06-016697.hdr.sgml : 20070112 20060410115857 ACCESSION NUMBER: 0000000000-06-016697 CONFORMED SUBMISSION TYPE: UPLOAD PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20060410 FILED FOR: COMPANY DATA: COMPANY CONFORMED NAME: BIOANALYTICAL SYSTEMS INC CENTRAL INDEX KEY: 0000720154 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 351345024 STATE OF INCORPORATION: IN FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: UPLOAD BUSINESS ADDRESS: STREET 1: 2701 KENT AVE CITY: WEST LAFAYETT STATE: IN ZIP: 47906-1382 BUSINESS PHONE: 3174634527 MAIL ADDRESS: STREET 1: 2701 KENT AVENUE CITY: WEST LAFAYETTE STATE: IN ZIP: 47906-1382 PUBLIC REFERENCE ACCESSION NUMBER: 0000927946-06-000006 LETTER 1 filename1.txt Via Facsimile and U.S. Mail Mail Stop 6010 April 7, 2006 Mr. Peter T. Kissinger President, Chairman and CEO Bioanalytical Systems, Inc. 2701 Kent Avenue West Lafayette, Indiana 47906 Re: Bioanalytical Systems, Inc. Form 10-K for Fiscal Year Ended September 30, 2005 Filed January 18, 2006 File No. 0-23357 Dear Mr. Kissinger: We have reviewed your March 28, 2006 response to our March 14, 2006 letter and have the following comment. In our comment, we ask you to provide us with information so we may better understand your disclosure. Please be as detailed as necessary in your explanation. After reviewing this information, we may raise additional comments. Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or on any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter. Form 10-K for the year ended September 30, 2005 Note 3. Acquisitions, page 40 1. We have read your response to comment 2. Tell us whether the value you ascribed to the facility and recorded in your financial statements at the acquisition date assumed it was FDA compliant. If so, tell us what the intangible asset "FDA compliant facility" represents. If not, it would appear to us that this asset is really part of the facility you acquired and should be part of its basis that you depreciate over the facility`s useful life. * * * * Please respond to this comment within 10 business days or tell us when you will provide us with a response. Please furnish a letter that keys your response to our comment and provide the requested information. Detailed letters greatly facilitate our review. Please file your letter on EDGAR under the form type label CORRESP. You may contact Sasha Parikh, Staff Accountant, at (202) 551- 3627 or Mary Mast, Review Accountant, at (202) 551-3613 if you have questions regarding the comments. In this regard, do not hesitate to contact me, at (202) 551-3679. Sincerely, Jim B. Rosenberg Senior Assistant Chief Accountant Peter T. Kissinger Bioanalytical Systems, Inc. April 7, 2006 Page 2 of 2 -----END PRIVACY-ENHANCED MESSAGE-----